EMA Publishes New Guidance for Qualified Person's Declaration on GMP Compliance of API - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EMA Publishes New Guidance for Qualified Person's Declaration on GMP Compliance of API


EMA has published a new guidance template for the qualified person’s declaration concerning GMP compliance of API manufacture.

The QP declaration template provides the basis for demonstrating compliance of the API manufacture with GMP requirements and ensures that the manufacturer has sufficient knowledge on the supply chain.

The objective of this guidance and the QP declaration template is to emphasize the importance of providing a valid declaration, to harmonize the format for the declaration, to forestall questions during assessment, and to enhance the efficiency of the regulatory process, including the timely processing of relevant regulatory submissions. While not mandatory, applicants are strongly encouraged to use the template to facilitate the validation of regulatory submissions and their review.

The QP declaration should be provided in support of applications for marketing authorizations, variation or renewal of a medicinal product(s) authorized in the Community, using EU or national procedures within the scope of the respective Directives.

QP declarations are required from each EEA finished-product manufacturing site and/or from each site of importation/batch certification. A single declaration from one QP from one of the registered finished product or batch-release sites, however, may be sufficient, if its basis is satisfactorily described and supported by technical agreements between these sites.

Source: EMA

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here